Amplification of MYCN correlates with high-risk SHH medulloblastoma, and MYCN can drive medulloblastoma in germline and non-germline genetically engineered mouse models (GEMMs) (Swartling et al., 2010, Swartling et al., 2012). The gene discussed is MYCN; the disease is medulloblastoma.